| Background:Infantile hemangioma(IH) is the most common benign lesions of infancy that occurs in 8.7%-12.7%, with up to 60% presenting in the head and neck region. It has a special lifecycle, which is divided into three phases (proliferative phase, involuting phase and involuted phase). Although most IHs regress spontaneously, and only a few need to be treated, but prognostic factor is still unknown. Therefore, the intervention treatment is necessary during the early proliferative phase to avoid the complications such as hemorrhage, ulceration, disfigurement and related dysfunction depending on there loction and size. In addition, the early intervention can relieve the mental burden of parents and avoid unpredictable psychological shadow of children. In 2008, Leaute-Labreze first reported the propranolol treatment of infantile hemangiomas with good effect. In 2010, Guo and Ni first reported successful outcome of a four-month old infant with superficial capillary hemangioma of the eyelid using timolol solution-another non-selective β-blockers. The authors now report the efficacy and safety of topical 0.5% timolol maleate eyedrops in the treatment of cutaneous superficial infantile hemangiomas in Chinese.Objective:To evaluate the short-term efficacy and safety of timolol in the treatment of superficial infantile hemangiomas.Method:From Mar.2012 to Nov.2012,124 patients with superficial infantile hemangiomas were included in the prospective study. Parents chose timolol eyedrops or observation. The characteristics of the tumor, including sex, age, site were recorded. The changes of tumor size, color, texture and side effects after treatment were also recorded. The response to treatment at 1 week, at 4 month was evaluated respectively by 3 independent special doctors. The results were categorized into three classs:class â… (ineffective:the lesion continues growing),class â…¡ (controlled growth:the lesion stops growing, and no significant change in size, color and texture), class â…¢ (promoted regression:the lesion becomes smaller, softer and lighter).Results:101 patients received timolol, and 23 patients were observed. At 1 week post-medication in the treated group, the lesion became softer and lighter.4 months after treatment, the overall response was classâ… in 8 patients (7.9%), class â…¡ in 36 patients (35.6%), and class â…¢ in 57 patients(56.4%), and complete clearance was achieved in 12 patients. There was no significant difference of effective rate between 1-6months group and 7-12months group (p>0.05). The regression rate of 1-6months group was significantly better than 7-12months group (p<0.05). No side effect was observed. But in the observed group, class â… in 15 patients(65.2%), class â…¡ in 7 patients (30.4%), and class â…¢ in 1 patients (4.3%). The regression rate and effective rate of treated group were significantly better than observed group (p<0.05).Conclusion:Topical timolol is an effective and safe treatment in superficial infantile hemangiomas. And it is one of the methods in the treatment of proliferative superficial infantile hemangiomas within 6 months. |
PDF Full Text Request